Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01454934 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 540
- Enrollment target
NCT01454934 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 540 participants.
The verdict
NCT01454934, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 540 participants
- Enrollment target
Study Summary
This is a randomized, open-label, multicenter, Phase 3 study, comparing efficacy and safety of eribulin with TPC in subjects with advanced and disease progression following at least two prior regimens for advanced disease, which should have included a platinum-based regimen.
Interventions
- DRUG Eribulin
- DRUG TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2011-12-09 |
| Est. Completion | 2016-05-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01454934
The ClinicalTrials.gov registry entry for NCT01454934 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eribulin is the first listed.
NCT01454934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01454934 about?
NCT01454934 is a clinical study titled "A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer". This is a randomized, open-label, multicenter, Phase 3 study, comparing efficacy and safety of eribulin with TPC in subjects with advanced and disease progression following at least two prior regimens for advanced disease, which should have included a platinum-based regimen.
What is the current status of trial NCT01454934?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 540 participants. The study started on 2011-12-09. Estimated completion is 2016-05-02.
What interventions are being tested in trial NCT01454934?
The interventions under investigation include: Eribulin (DRUG), TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT01454934?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.